CHIPSCREEN: The Pioneer of Original New Drugs
In a world that develops and speeds up drastically every year, time is becoming an increasingly valuable commodity. It is becoming evidently clear now that in order to win life, one must win time. This is what drove one scientist, Dr. Lu Xianping down in Shenzhen, to spend a decade researching and developing the cancer treatment drug known as Chidamide. With this much more affordable drug, the survival time is significantly longer for cancer sufferers and also of a much higher quality of life.
Chipscreen is a bio-tech company, headquartered in Shenzhen, that was founded by an internationally experienced team of scientists that specialize in the development of original small molecule drugs. Its founder, Dr. Lu Xianping, received a doctorate from Peking Union Medical College in 1988, before attending the University of California San Diego School of Medicine as a postdoctoral fellow. He went on to participate in the creation of biomedical companies engaged in drug research and development in 1994. Around this time, the life science industry was undergoing rapid growth and, with the rise of a number of new biopharmaceutical companies, scientific research started shifting towards the market.
While at a gathering for study abroad students, Lu Xianping started a discussion about China’s stagnation in medicine development, despite China’s rapid growth in recent years. Although, China has the largest number of pharmaceutical companies in the world, 98% of the products are generic and lack innovation. Lu Xianping and the other Chipscreen founders vowed to return to business, and innovate China’s pharmaceutical industry.
In 2000, Lu Xianping first returned back to Tsinghua University to start Chipscreen with his affiliates. Cheng Jing. Dr.Ning Zhiqiang, Dr.Shi Leming, and Dr.Hu Weiming followed in his footsteps. The team financed and founded Chipscreen in 2001 and, what started as a 50 million Yuan venture, has now reached R&D investment levels of nearly 10 billion Yuan.
The Birth of New Drugs
The drug development process is one that is long and extremely difficult to succeed in. Chipscreen’s innovation differentiates them from competition, eliminating risk, and even allowing them to accelerate the drug research and development phase.
In January 2015, Chipscreen’s anti-cancer drug, Chidamide, was approved for the global market, becoming China’s first authorized drug to be used in the United States, Japan, and other developed countries. This marks a great milestone in China’s pharmaceutical history.
The news of an emerging anti-cancer drug that was created in China shocked the Pharmaceutical industry worldwide. Dr.Lu Xianping became known as “China ‘s pioneer of new drugs,” and was featured in a number of established media outlets such as Time, Business Week, Forbes, and Fortune .
In addition to Chidamide, Chipscreen has produced a number of different drugs, including Chiglitazar and Chiauranib. In total, it has formed six classifications of drugs, which include dozens of innovative drugs across different stages. From the laboratory to the clinical research stage, all drugs are protected with global intellectual property protection.
Chipscreen has been researching and developing drugs in the cancer, diabetes, immune and endocrine diseases fields for the last 15 years. Currently, it has 73 applications for global invention patents, 45 of which have already been authorized, and has published over 30 papers in academic journals worldwide.
Shenzhen is currently the most efficient and fastest growing city in China. It has an array of global and innovative companies emerging, one of which is Chipscreen. Due to its significant scientific breakthroughs and achievements in terms of its global patents, Chipscreen has been listed as a 2016 Shenzhen 100 Top 10 Risers.
“In the field of biomedicine, core technology, and patenting inventions are extremely important. Only through independent research and development can our medicine companies hope to succeed,” Dr.Lu Xianping said. Chipscreen’s creativity in the medicine industry is helping to shift the mentality in China from imitation to innovation.